BeOne signs $2B deal for option on preclinical trispecific antibody from China’s Huahui
BeOne signs $2B deal for option on preclinical trispecific antibody from China’s Huahui
BeOne signs $2B deal for option on preclinical trispecific antibody from China’s Huahui